|Oxford Pharm Gp
||EPS - Basic
||Market Cap (m)
|Pharmaceuticals & Biotechnology
Oxford Pharm Gp Share Discussion Threads
Showing 776 to 800 of 800 messages
|Mmmm.... a bit of a false dawn, today - the rise appears to have been soon sold into, even though still standing higher than previouly.
|OXP has moved up quite a % bit in the last week. Looks quite strongish to me, with a 100k lot taken at 3.03p just this minute.
|There were some large trade at 3p and above. I feel that there is no smoke without fire and they will be pulled back up. I unfortunately took a profit at 2.18 and missed on the rise. Anyone any have any sensible entry point views?|
|Dips being bought, looking for another run to 3.5p pre news. Good news should see this back to 10p placing price.
It can happen. Just tuck them away and trade something else IMO.|
|PU, many thanks for the snippet on surface transforms. I will respond in more detail later, I'm currently on a plane (to Vegas) waiting to take off, hence the brevity.|
Re SCE - I think you are a holder - Had a chat with DB recently and also looked at web cast - Time lines extended but will continue to hold risk/reward (imo) still tilted in favour of reward. (If of any use to you) Usual cautions apply|
No, I remain very sceptical|
|I'm not sure they've given up on the GI part.
"This study is to help development of a new version of Ibuprofen, called Ibuprofen-LDH. Ibuprofen-LDH will be used as a treatment for muscular pains, headache, fever etc. This new version of ibuprofen is expected to produce fewer stomach/intestine related side effects when compared to many existing marketed formulations of Ibuprofen."
I sure hope they haven't as I see the GI part as the most interesting.|
Can you translate please into consumer speak and also have you changed your mind about the technology (your post 730 above) so as to make this worth looking at again.|
|Good to see that they have given up trying to obtain GI safe claims for an OTC formula, as this was always a non-starter as far as I was concerned. I doubt if they will get improved taste masking with faster acting, but they should be able to achieve taste masking without the speed claims.|
|Very good news. Having trust in an increasing share price|
|Update...we need advice from the experts on this.|
|hmmm..has been a bit quiet lately|
|another million buy gone through. Serious cash|
|Quite happy with that.|
meanwhile back at the ranch
|They are at it
Dropped the share price over lunch to gather shares for the one million buyer|
|Quite some drop as well
Was the drop justified?|
|It's been some rally! The news needs to be very good I guess to justify this re rating but the 22 million in cash 💰 always puts a limit on the downside. I wonder if some company is sniffing around?|
|News can land anytime and if it's good then a rerate will ensue.
"Dosing for all three study parts is due to complete by the end of the second quarter of 2017, with first readouts are also expected in the second quarter.
Oxford Pharmascience also said it expects responses from the US Food and Drug Administration over the regulatory pathway for OXPzero ibuprofen in the first quarter of 2017."|
|..and so it came to pass..|
|This is just how OXP moves don't you know.|
|very nice. Vertical take off.
FOLLOW HASHTAG TRICKSTER
|Like yesterday any sells get soaked up and forward it goes again|
|Feels like a reasonable 6p on it's way and especially if an update includes a customer win. Seeing Woodford funding itat 10p gives me confidence not to risk trading out of it. Could be one of those where buying on the way up on any dips makes sense this time. I may have to pluck up the courage to do that myself.|
|Flying again. Doubled for me. Taken my stake out now in full and will wait for news. Those who were selling at 1.6 and below cash a short while ago must be fed up|